Potential role of green tea extract and epigallocatechin gallate in preventing bisphenol A-induced metabolic disorders in rats: Biochemical and molecular evidence

Duchenne muscular dystrophy is a frequent muscular disorder caused by mutations in the gene encoding dystrophin, a cytoskeletal protein that contributes to the stabilization of muscle fiber membrane during muscle activity. Affected individuals show progressive muscle wasting that generally causes death by age 30. In this study, the dystrophic mdx 5Cv mouse model was used to investigate the effects of green tea extract, its major component (−)-epigallocatechin gallate, and pentoxifylline on dystrophic muscle quality and function. Three-week-old mdx 5Cv mice were fed for either 1 or 5 wk a control chow or a chow containing the test substances. Histological examination showed a delay in necrosis of the extensor digitorum longus muscle in treated mice. Mechanical properties of triceps suræ muscles were recorded while the mice were under deep anesthesia. Phasic and tetanic tensions of treated mice were increased, reaching values close to those of normal mice. The phasic-to-tetanic tension ratio was corrected. Finally, muscles from treated mice exhibited 30–50% more residual force in a fatigue assay. These results demonstrate that diet supplementation of dystrophic mdx 5Cv mice with green tea extract or (−)-epigallocatechin gallate protected muscle against the first massive wave of necrosis and stimulated muscle adaptation toward a stronger and more resistant phenotype.

Download Full-text

Kinetics of Reduction of Ferrylmyoglobin by (−)-Epigallocatechin Gallate and Green Tea Extract

Journal of Agricultural and Food Chemistry ◽

10.1021/jf011535u ◽

2002 ◽

Vol 50 (10) ◽

pp. 2998-3003 ◽

Cited By ~ 27

Author(s):

Min Hu ◽

Leif H. Skibsted

Keyword(s):

Green Tea ◽

Epigallocatechin Gallate ◽

Green Tea Extract ◽

Tea Extract ◽

Kinetics Of ◽

Kinetics Of Reduction

Download Full-text

Bioavailability and antioxidant effect of epigallocatechin gallate administered in purified form versus as green tea extract in healthy individuals

The Journal of Nutritional Biochemistry ◽

10.1016/j.jnutbio.2005.03.003 ◽

2005 ◽

Vol 16 (10) ◽

pp. 610-616 ◽

Cited By ~ 110

Author(s):

Susanne M. Henning ◽

Yantao Niu ◽

Yong Liu ◽

Nicolas H. Lee ◽

Yukihiko Hara ◽

...

Keyword(s):

Green Tea ◽

Epigallocatechin Gallate ◽

Antioxidant Effect ◽

Green Tea Extract ◽

Healthy Individuals ◽

Form Versus ◽

Tea Extract

Download Full-text

Green Tea Potentially Ameliorates Bisphenol A-Induced Oxidative Stress: AnIn VitroandIn SilicoStudy

Biochemistry Research International ◽

10.1155/2014/259763 ◽

2014 ◽

Vol 2014 ◽

pp. 1-9 ◽

Cited By ~ 14

Author(s):

Hiral Suthar ◽

R. J. Verma ◽

Saumya Patel ◽

Y. T. Jasrai

Keyword(s):

Oxidative Stress ◽

Bisphenol A ◽

Green Tea ◽

Binding Capacity ◽

Venous Blood ◽

Green Tea Extract ◽

High Dose ◽

Healthy Human ◽

Tea Extract ◽

Dose Dependent

The present investigation was an attempt to elucidate oxidative stress induced by bisphenol A on erythrocytes and its amelioration by green tea extract. For this, venous blood samples from healthy human adults were collected in EDTA vials and used for preparation of erythrocytes suspension. When erythrocyte suspensions were treated with different concentrations of BPA/H2O2, a dose-dependent increase in hemolysis occurred. Similarly, when erythrocytes suspensions were treated with either different concentrations ofH2O2(0.05–0.25 mM) along with BPA (50 μg/mL) or 0.05 mMH2O2along with different concentrations of BPA (50–250 μg/mL), dose-dependent significant increase in hemolysis occurred. The effect of BPA andH2O2was found to be additive. For the confirmation, binding capacity of bisphenol A with erythrocyte proteins (hemoglobin, catalase, and glutathione peroxidase) was inspected using molecular docking tool, which showed presence of various hydrogen bonds of BPA with the proteins. The present data clearly indicates that BPA causes oxidative stress in a similar way asH2O2. Concurrent addition of different concentrations (10–50 μg/mL) of green tea extract to reaction mixture containing high dose of bisphenol A (250 μg/mL) caused concentration-dependent amelioration in bisphenol A-induced hemolysis. The effect was significant (P<0.05). It is concluded that BPA-induced oxidative stress could be significantly mitigated by green tea extract.

Download Full-text

The MIRACLE trial: A randomized, controlled trial comparing green tea extract versus placebo for the prevention of metachronous colon adenomas in a screening population.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.3_suppl.tps786 ◽

2015 ◽

Vol 33 (3_suppl) ◽

pp. TPS786-TPS786 ◽

Cited By ~ 1

Author(s):

Thomas Jens Ettrich ◽

Julia Stingl ◽

Rainer Muche ◽

Katrin Claus ◽

Baerbel Reiser ◽

...

Keyword(s):

Green Tea ◽

Controlled Trial ◽

Epigallocatechin Gallate ◽

Genetic Alterations ◽

Colorectal Polyps ◽

Green Tea Extract ◽

Colorectal Adenomas ◽

Tissue Samples ◽

Increased Risk ◽

Tea Extract

TPS786 Background: Prevention of colorectal cancer is a major health care issue. After polypectomy there is an increased risk of polyp recurrence and various means of chemoprevention have been tried to prevent this. NSAIDs have been shown to be effective but confer side effects such as gastrointestinal bleeding. Nutraceuticals such as polyphenols from tea plants have demonstrated remarkable therapeutic and preventive effects in molecular, epidemiological and some clinical trials. However, their value in preventing colorectal polyps has not been demonstrated in a large, randomized trial. The beneficial safety profile of decaffeinated green tea extract and accumulating evidence of its cancer preventive potential justify and require, in our view, a validation of this compound for the nutriprevention of colorectal adenoma. Good accessibility and low costs might render this neutraceutical a top candidate for wider use as nutritional supplement in colon cancer prevention. Methods: Randomized, double blinded, placebo-controlled, multicenter trial. After a one month run-in period with verum, 918 patients (age: 50-80 years) who have undergone polypectomy within the last 6 months will be randomized to receive either decaffeinated green tea extract (containing 150 mg epigallocatechin gallate (EGCG) two times daily) or placebo over a period of three years. Primary outcome: Incidence of metachronous colorectal adenomas (tubulovillous, tubular, villous, serrated lesions) at the 3 year follow-up colonoscopy. Secondary outcomes: Occurrences, number, localization, size and histological subtypes of adenomas, frequency of colorectal carcinoma. In addition, genetic and biochemical biomarkers in blood samples and genetic alterations (Ras, B-raf, microRNAs) in tissue samples of adenomas will be analyzed (biobanking subprojects). Additionally, nutrikinetics and nutrigenetics of EGCG and other catechins will be assessed in healthy volunteers. Patient recruitment has started in November 2011. At September 2014, 785 patients were recruited and 651 patients were randomized. We expect the last patient out in Spring 2018. (Trial identifier NCT01360320) Clinical trial information: NCT01360320.

Download Full-text